SARCOME 09_Intergroup Study (SFCE/GSF-GETO) OS2006 - Zoledronate Osteosarcoma Treatment Protocol for osteosarcoma of the child, adolescent and adult including: - A randomized trial - And biological studies.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514756-32-00

Acronym

UC-0150/ 0603

Enrollment

653

Registered

2024-08-12

Start date

2007-03-19

Completion date

Unknown

Last updated

2024-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

High grade osteosarcoma

Brief summary

Event-free survival at 3 years.

Detailed description

Overall survival,, Histological response,, Short-term (NCI-CTC v3) and long-term toxicity,, Bone metabolism,, Quality of life.

Interventions

DRUGZometa 4 mg/100 ml solution for infusion

Eligibility

Sex/Gender

All

Age

0 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Event-free survival at 3 years.	—

Secondary

Measure	Time frame
Overall survival,, Histological response,, Short-term (NCI-CTC v3) and long-term toxicity,, Bone metabolism,, Quality of life.	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026